
STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.
Recent stories from STAT Biotech.

Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.

“These results, the fact that they're negative, does not invalidate that inflammation plays a very important role in cardiovascular disease."

New cases show AAV gene therapies like Zolgensma carry tumor risks, raising key concerns for SMA patients and gene therapy researchers in general.
Pithy intro text about the biopharma milieu. Novartis cites more tumor reports after Zolgensma Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene therapy…

Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, Zolgensma.

Three years ago, a trial for a sickle cell gene-editing therapy a decade in the making ended abruptly after the first patient suffered a serious adverse event. Now, the therapy…

A new study could help doctors figure out what medicine to prescribe for cholesterol when statins don't cut it: It's “answering a really challenging clinical question."

Despite widespread opposition, Medicare will finalize a controversial proposal that will prevent providers, such as hospitals, from using third parties to deliver remote patient monitoring services.

Rasonque, Revolution Medicines' new pancreatic cancer drug, is off to one of the best oncology drug launches in history.

Shares of ProMis Neurosciences, developer of a treatment for Alzheimer’s disease, sold off sharply last week. A closer look at the reason why — and whether it holds up.

Following patient deaths, China restricts investigator-initiated biotech trials, leaving rare disease families and US investors facing an uncertain future.

Sanders could use his role in crafting the FDA funding bill to push for reforms.

Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.